Mesenchymal stem cells (MSCs) and De Quervains


Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in various tissues throughout the body, including the bone marrow, adipose tissue, and skin. MSCs have the ability to differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells). MSCs were first isolated from the bone marrow in the early 1970s, and since then, much research has been conducted on their potential therapeutic applications. In particular, MSCs have shown promise in the treatment of a variety of degenerative diseases, such as osteoarthritis, diabetes, and cardiovascular disease. One potential application of MSCs is the treatment of de Quervain's disease, a condition that results in the inflammation of the tendons in the thumb and wrist. De Quervain's disease is a common condition, affecting up to 5% of the population. The condition is often caused by repetitive motion, such as typing or writing. There is currently no cure for de Quervain's disease, and the only available treatments are aimed at reducing the symptoms. However, these treatments are often only partially effective, and can have a number of side effects. MSCs have shown promise in the treatment of de Quervain's disease. In a study published in 2016, patients with de Quervain's disease were injected with MSCs derived from their own bone marrow. The results of the study showed that the MSCs were able to reduce the symptoms of the condition, with some patients experiencing a complete remission. MSCs are a promising new treatment for de Quervain's disease, and further research is required to confirm their efficacy. However, the use of MSCs in the treatment of de Quervain's disease is still in its early stages, and more research is needed to determine the long-term safety and efficacy of this treatment.

 "Mesenchymal Stem Cells Use in the Treatment of Tendon Disorders." Accessed 26 Oct. 2022.

 "Human mesenchymal stem cells (MSCs) for treatment towards ...." 4 Nov. 2016, Accessed 26 Oct. 2022.

 "Stem cell therapy and PRP therapy for De Quervain's Tenosynovitis." Accessed 26 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
Myers cocktail/NAD50,000,0001N/A

Tendon(1st Compartment)5,000,00015,000,000